A senior scientist at the U.S. Centers for Disease Control and Prevention has resigned, warning that changes in leadership ...

This Danish series, about a morning show in crisis, is light but not dumb, credible but still arch. It is also very different ...

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Canaccord downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $13, down from $39, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Seth MacFarlane has shared a behind-the-scenes mini-documentary to showcase the making of ‘Lush Life: The Lost Sinatra ...

There’s not much fun in the new 2025 A5, but that’s why Audi makes the S5. Otherwise, there’s little to gripe about with this ...